| Sep 30 |
Repare Therapeutics Announces Phase 1 Data Highlighting Camonsertib in Combination with Radiotherapy Treatment Presented at the ASTRO Annual Meeting
|
| Sep 27 |
Repare Therapeutics Inc. (NASDAQ:RPTX) is definitely on the radar of institutional investors who own 36% of the company
|
| Sep 23 |
Repare Therapeutics Announces New Data Underscoring Need for Additional Treatment Solutions for Patients with Metastatic Gynecologic Cancers
|
| Sep 13 |
Repare Therapeutics to Present Data from Phase 1/2 TRESR Clinical Trial Evaluating Camonsertib Monotherapy in Multiple Advanced Solid Tumors Harboring ATM Loss-of-Function at ESMO Congress 2024
|
| Aug 30 |
Repare: Q4 2024 Is A Major Inflection Point With Lunresertib, Camonsertib Data
|
| Aug 29 |
Repare Therapeutics cuts quarter of its workforce and prioritises clinical assets
|
| Aug 29 |
Repare Therapeutics Inc. (RPTX): A Promising Penny Stock in Canada’s Evolving Economic Landscape
|
| Aug 28 |
Repare to focus on clinical assets, cut 25% of workforce
|
| Aug 28 |
Repare Therapeutics Announces Strategic Reprioritization to Focus on Broad Clinical Portfolio
|
| Aug 27 |
Repare Therapeutics to Participate in Two Upcoming Investor Conferences
|
